TD Cowen Maintains Buy on Krystal Biotech, Lowers Price Target to $380

Benzinga · 3d ago
TD Cowen analyst Ritu Baral maintains Krystal Biotech (NASDAQ:KRYS) with a Buy and lowers the price target from $403 to $380.